François Lucia, Jacques Lamour, Margaux Geier, Vincent Bourbonne, Fanny Pinot, Malik Nebbache, Frédérique Blanc-Béguin, Simon Hennebicq, Maëlle Mauguen, Kevin Kerleguer, Ulrike Schick, Olivier Pradier, Grégoire Le Gal, Pierre-Yves Salaun, David Bourhis, Pierre-Yves Le Roux
{"title":"利用镓-68灌注PET/CT功能定位的剂量-体积参数预测肺立体定向放射治疗后健康相关生活质量结果","authors":"François Lucia, Jacques Lamour, Margaux Geier, Vincent Bourbonne, Fanny Pinot, Malik Nebbache, Frédérique Blanc-Béguin, Simon Hennebicq, Maëlle Mauguen, Kevin Kerleguer, Ulrike Schick, Olivier Pradier, Grégoire Le Gal, Pierre-Yves Salaun, David Bourhis, Pierre-Yves Le Roux","doi":"10.1186/s13014-025-02685-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The PEGASUS trial was the first study to evaluate and demonstrate the benefits of <sup>68</sup>Ga-perfusion PET/CT in the lung stereotactic body radiotherapy (SBRT) planning process in preserving functional lung volumes while respecting target volume coverage and doses to other organs at risk. Here we report the prespecified exploratory endpoint of SBRT on health-related quality of life (HRQoL).</p><p><strong>Methods: </strong>In this single-center prospective study, we recruited patients planned to be treated in our radiotherapy department with SBRT for primary or secondary lung tumors. Patient-reported outcomes were assessed at the first visit, 1 month, 3 months and every 3 months until 12 months after SBRT using the European Organisation for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 items (QLQ-C30), the EORTC Quality of Life Questionnaire Lung Cancer 13 items (QLQ-LC13), and the European Quality of Life 5 Dimensions-5 Level (EQ-5D-5 L) questionnaire. The key exploratory HRQoL endpoints (analyzed for all patients who completed at least QLQ-C30 at least one time point after SBRT) were baseline-to-early change (between 1 month and 3 month) and baseline-to-late change (between 6 month and 12 month) in the QLQ-C30 global health status (GHS)/quality-of-life (QoL) score and in the deterioration of the dyspnea (patient-reported lung toxicity). Explorative analysis of the impact of baseline HRQoL, patient- and SBRT-related characteristics, including PET perfusion-based functional parameters, on the change in HRQoL from baseline was analyzed using univariate analysis.</p><p><strong>Results: </strong>Of the 60 patients included, 39 were analyzable as early-onset and 22 as late-onset. Thirteen (33%) and 7 (32%) patients had a deterioration of QoL. In univariate analysis, maximal dose to the heart, doses to the functional lung volume and pulmonary functional test parameters were significantly associated with the early deterioration of HRQoL. Only doses to the functional lung volume were significantly associated with the late deterioration of HRQoL.</p><p><strong>Conclusion: </strong>In our study, increased radiation doses in functional lung volume PET bases dose parameters were significantly associated with a decrease of HRQoL unlike anatomic lung parameters. Functional lung avoidance planning guided by perfusion PET/CT may be a simple and noninvasive method to improve HRQoL in patients treated with lung SBRT.</p>","PeriodicalId":49639,"journal":{"name":"Radiation Oncology","volume":"20 1","pages":"108"},"PeriodicalIF":3.3000,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12243402/pdf/","citationCount":"0","resultStr":"{\"title\":\"Prediction of health-related quality-of-life results after lung stereotactic body radiotherapy using dose-volume parameters from functional mapping on Gallium-68 perfusion PET/CT.\",\"authors\":\"François Lucia, Jacques Lamour, Margaux Geier, Vincent Bourbonne, Fanny Pinot, Malik Nebbache, Frédérique Blanc-Béguin, Simon Hennebicq, Maëlle Mauguen, Kevin Kerleguer, Ulrike Schick, Olivier Pradier, Grégoire Le Gal, Pierre-Yves Salaun, David Bourhis, Pierre-Yves Le Roux\",\"doi\":\"10.1186/s13014-025-02685-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The PEGASUS trial was the first study to evaluate and demonstrate the benefits of <sup>68</sup>Ga-perfusion PET/CT in the lung stereotactic body radiotherapy (SBRT) planning process in preserving functional lung volumes while respecting target volume coverage and doses to other organs at risk. Here we report the prespecified exploratory endpoint of SBRT on health-related quality of life (HRQoL).</p><p><strong>Methods: </strong>In this single-center prospective study, we recruited patients planned to be treated in our radiotherapy department with SBRT for primary or secondary lung tumors. Patient-reported outcomes were assessed at the first visit, 1 month, 3 months and every 3 months until 12 months after SBRT using the European Organisation for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 items (QLQ-C30), the EORTC Quality of Life Questionnaire Lung Cancer 13 items (QLQ-LC13), and the European Quality of Life 5 Dimensions-5 Level (EQ-5D-5 L) questionnaire. The key exploratory HRQoL endpoints (analyzed for all patients who completed at least QLQ-C30 at least one time point after SBRT) were baseline-to-early change (between 1 month and 3 month) and baseline-to-late change (between 6 month and 12 month) in the QLQ-C30 global health status (GHS)/quality-of-life (QoL) score and in the deterioration of the dyspnea (patient-reported lung toxicity). Explorative analysis of the impact of baseline HRQoL, patient- and SBRT-related characteristics, including PET perfusion-based functional parameters, on the change in HRQoL from baseline was analyzed using univariate analysis.</p><p><strong>Results: </strong>Of the 60 patients included, 39 were analyzable as early-onset and 22 as late-onset. Thirteen (33%) and 7 (32%) patients had a deterioration of QoL. In univariate analysis, maximal dose to the heart, doses to the functional lung volume and pulmonary functional test parameters were significantly associated with the early deterioration of HRQoL. Only doses to the functional lung volume were significantly associated with the late deterioration of HRQoL.</p><p><strong>Conclusion: </strong>In our study, increased radiation doses in functional lung volume PET bases dose parameters were significantly associated with a decrease of HRQoL unlike anatomic lung parameters. Functional lung avoidance planning guided by perfusion PET/CT may be a simple and noninvasive method to improve HRQoL in patients treated with lung SBRT.</p>\",\"PeriodicalId\":49639,\"journal\":{\"name\":\"Radiation Oncology\",\"volume\":\"20 1\",\"pages\":\"108\"},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2025-07-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12243402/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Radiation Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s13014-025-02685-w\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Radiation Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13014-025-02685-w","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Prediction of health-related quality-of-life results after lung stereotactic body radiotherapy using dose-volume parameters from functional mapping on Gallium-68 perfusion PET/CT.
Background: The PEGASUS trial was the first study to evaluate and demonstrate the benefits of 68Ga-perfusion PET/CT in the lung stereotactic body radiotherapy (SBRT) planning process in preserving functional lung volumes while respecting target volume coverage and doses to other organs at risk. Here we report the prespecified exploratory endpoint of SBRT on health-related quality of life (HRQoL).
Methods: In this single-center prospective study, we recruited patients planned to be treated in our radiotherapy department with SBRT for primary or secondary lung tumors. Patient-reported outcomes were assessed at the first visit, 1 month, 3 months and every 3 months until 12 months after SBRT using the European Organisation for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 items (QLQ-C30), the EORTC Quality of Life Questionnaire Lung Cancer 13 items (QLQ-LC13), and the European Quality of Life 5 Dimensions-5 Level (EQ-5D-5 L) questionnaire. The key exploratory HRQoL endpoints (analyzed for all patients who completed at least QLQ-C30 at least one time point after SBRT) were baseline-to-early change (between 1 month and 3 month) and baseline-to-late change (between 6 month and 12 month) in the QLQ-C30 global health status (GHS)/quality-of-life (QoL) score and in the deterioration of the dyspnea (patient-reported lung toxicity). Explorative analysis of the impact of baseline HRQoL, patient- and SBRT-related characteristics, including PET perfusion-based functional parameters, on the change in HRQoL from baseline was analyzed using univariate analysis.
Results: Of the 60 patients included, 39 were analyzable as early-onset and 22 as late-onset. Thirteen (33%) and 7 (32%) patients had a deterioration of QoL. In univariate analysis, maximal dose to the heart, doses to the functional lung volume and pulmonary functional test parameters were significantly associated with the early deterioration of HRQoL. Only doses to the functional lung volume were significantly associated with the late deterioration of HRQoL.
Conclusion: In our study, increased radiation doses in functional lung volume PET bases dose parameters were significantly associated with a decrease of HRQoL unlike anatomic lung parameters. Functional lung avoidance planning guided by perfusion PET/CT may be a simple and noninvasive method to improve HRQoL in patients treated with lung SBRT.
Radiation OncologyONCOLOGY-RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
CiteScore
6.50
自引率
2.80%
发文量
181
审稿时长
3-6 weeks
期刊介绍:
Radiation Oncology encompasses all aspects of research that impacts on the treatment of cancer using radiation. It publishes findings in molecular and cellular radiation biology, radiation physics, radiation technology, and clinical oncology.